Wednesday May 30, 7:21 am Eastern Time
Press Release
Isonics Enters Into Joint Development Program With Microprocessor Manufacturer
GOLDEN, Colo.--(BUSINESS WIRE)--May 30, 2001--Isonics Corporation (NasdaqSC: ISON/ISONW) and (Frankfurt: IO9) a leader in the development of isotopically pure silicon-28 wafers for the semiconductor industry announced that it has entered into a one-year silicon-28 joint development program with a major microprocessor manufacturer.
James E. Alexander, Isonics President & CEO commented, ``By entering into this program Isonics has taken a significant step toward the commercialization of silicon-28. We expect that the work to be undertaken as a result of this program will not only validate earlier work done by our other research partners, but will also lead to the commercial development of silicon-28 based semiconductor and microprocessor products. We committed to achieving this milestone a year ago and hope to be able to announce additional details of the planned effort in the coming months.''
Dr. Stephen J. Burden, Isonics' VP of Semiconductor Materials, added, ``Initial testing confirmed that our silicon-28 wafers met industry quality standards and could be substituted for normal silicon wafers in a production fab. This program calls for Isonics to supply several versions of silicon-28 epitaxial wafers and eventually silicon-28 bulk wafers. Making and rigorously testing state-of-the-art microprocessors is the only way to accurately quantify the benefits of high thermal conductivity silicon-28 in this application. By testing the entire spectrum of silicon-28 wafers, we believe that we will find the proper balance between performance and cost.''
Isonics is a world leader in isotopically engineered materials and produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Isonics also markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. For additional information visit isonics.com.
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB for the year ended April 30, 2000, and its quarterly report on Form 10-QSB for the nine months ended January 31, 2001, both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
Cameron Associates
Michael Brod, 212/245-8800
michael@cameronassoc.com
or
Isonics Corporation
Stephen J. Burden
sburden@isonics.com |
